
Antiviral agent 17
CAS No. 158227-81-7
Antiviral agent 17( —— )
Catalog No. M35420 CAS No. 158227-81-7
Antiviral agent 17 (Compound 4) is an anti-infection compound with strong antiviral effects, demonstrated by an EC50 of 0.015 μM in a human replicon assay, and effective against murine norovirus.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 42 | Get Quote |
![]() ![]() |
10MG | 65 | Get Quote |
![]() ![]() |
25MG | 124 | Get Quote |
![]() ![]() |
50MG | 196 | Get Quote |
![]() ![]() |
100MG | 286 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameAntiviral agent 17
-
NoteResearch use only, not for human use.
-
Brief DescriptionAntiviral agent 17 (Compound 4) is an anti-infection compound with strong antiviral effects, demonstrated by an EC50 of 0.015 μM in a human replicon assay, and effective against murine norovirus.
-
DescriptionAntiviral agent 17 (Compound 4) is an anti-infection agent. Antiviral agent 17 retains its antiviral effect in a human replicon assay (EC50 = 0.015 μM). Antiviral agent 17 results in good antiviral activity against murine norovirus. Antiviral agent 17 has the potential for the research of infectious and malignant diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorHCV Protease | Antiviral
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number158227-81-7
-
Formula Weight266.25
-
Molecular FormulaC11H14N4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO[C@H]1[C@H](C=2N3C(=CC2)C(N)=NC=N3)O[C@H](CO)[C@H]1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li Q, et al. Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides. Eur J Med Chem. 2020 Jun 1;195:112198.?
molnova catalog



related products
-
PDCD4-IN-1
PDCD4-IN-1, a PDCD4 inhibitor (Kd : 350 nM), promotes BDNF expression in hippocampal neuronal cells HT-22.
-
EZM0414 TFA
EZM0414 TFA (SETD2-IN-1 TFA) is a SETD2 inhibitor with anticancer and antiproliferative effects for the study of leukemia and immune dysfunction.
-
Ontuxizumab
Ontuxizumab (MORAb-004) is a potent IgG1/κ monoclonal antibody targeting endomelanic acid with anti-tumor effects.